Sociodemographic characteristics, humoral and cellular responses from cohort 1 (immunosuppressed IMRD ISP+), cohort 2 (immunocompetent IMRD ISP−) and cohort 3 (healthy controls)
| IMRD ISP+ (immunosuppressed) (n=100) | IMRD ISP− (immunocompetent) (n=47) | Healthy controls (n=50) | P value (cohorts 1/2) | P value (cohorts 2/3) | |
| Median age | 66.6 (60.5–75) | 68.5 (63–75) | 51.2 (32–66) | 0.36 | 0.09 |
| Female (n, %) | 60 (60) | 36 (77) | 32 (64) | 0.06 | 0.18 |
| Glucocorticoid cumulative dose | 9901±1162 | 5083±9820 | NA | 0.001* | NA |
| Methotrexate cumulative dose | 3570±4500 | 1193±2550 | NA | 0.004* | NA |
| Seroconversion rate (n, %) | 55 (55) | 38 (80) | 50 (100) | 0.02* | 0.03* |
| IgG anti-spike (BAU/mL) | 254±280 | 458.6±2960 | 526.3±2078 | 0.007* | 0.18 |
| CD4 T-cell responders (n, %) | 52 (52) | 35 (75) | 50 (100) | 0.01* | 0.02* |
| CD8 T-cell responders (n, %) | 53 (53) | 36 (77) | 46 (92) | 0.01* | 0.04* |
BAU, binding antibody unit; IMRD, immune-mediated inflammatory rheumatic disease.